Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Allergy and Clinical Immunology

• Publication date

  2010-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.jaci.2010.08.014PMID 21047676PMCID PMC3002752
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of selective PDE4B inhibitors.

  2009cited by this paper
• Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.

  2009cited by this paper
• PDE4 inhibitors: current status

  2008cited by this paper
• Mast cell-derived TNF contributes to airway hyperreactivity, inflammation, and TH2 cytokine production in an asthma model in mice.

  2007cited by this paper
• Evidence for a Locus in 1p31 Region Specifically Linked to the Co-Morbidity of Asthma and Allergic Rhinitis in the EGEA Study

  2007cited by this paper
• Differential Expression and Function of Phosphodiesterase 4 (PDE4) Subtypes in Human Primary CD4+ T Cells: Predominant Role of PDE4D1

  2007cited by this paper
• Mast Cell-Associated TNF Promotes Dendritic Cell Migration1

  2006cited by this paper
• Specific Role of Phosphodiesterase 4B in Lipopolysaccharide-Induced Signaling in Mouse Macrophages 1

  2005cited by this paper
• Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.

  2005cited by this paper
• Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias.

  2005cited by this paper
• The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma

  2004cited by this paper
• TCR- and CD28-Mediated Recruitment of Phosphodiesterase 4 to Lipid Rafts Potentiates TCR Signaling1

  2004cited by this paper
• A Critical Role for Eosinophils in Allergic Airways Remodeling

  2004cited by this paper
• Asthma: mechanisms of disease persistence and progression.

  2004cited by this paper
• Nonredundant Function of Phosphodiesterases 4D and 4B in Neutrophil Recruitment to the Site of Inflammation1

  2004cited by this paper
• Positive and negative regulation of T-cell activation through kinases and phosphatases.

  2003cited by this paper
• PDE4D plays a critical role in the control of airway smooth muscle contraction

  2003cited by this paper
• Regulation of T-Cell Activation by Phosphodiesterase 4B2 Requires Its Dynamic Redistribution during Immunological Synapse Formation

  2003cited by this paper
• Interleukins-4, -5, and -13: emerging therapeutic targets in allergic disease.

  2002cited by this paper
• Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis.

  2002cited by this paper
• Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses

  2002cited by this paper
• Tumor necrosis factor-alpha negatively regulates airway hyperresponsiveness through gamma-delta T cells.

  2001cited by this paper
• Specific Migratory Dendritic Cells Rapidly Transport Antigen from the Airways to the Thoracic Lymph Nodes

  2001cited by this paper
• Antiasthmatic effect of YM976, a novel PDE4 inhibitor, in guinea pigs.

  2001cited by this paper
• Critical Role for IL-13 in the Development of Allergen-Induced Airway Hyperreactivity1

  2001cited by this paper
• Tumor Necrosis Factor- α Negatively Regulates Airway Hyperresponsiveness through γδ T Cells

  2001cited by this paper
• Interleukin (IL)-5 but not immunoglobulin E reconstitutes airway inflammation and airway hyperresponsiveness in IL-4-deficient mice.

  2000cited by this paper
• Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D.

  2000cited by this paper
• IL-10 is necessary for the expression of airway hyperresponsiveness but not pulmonary inflammation after allergic sensitization.

  2000cited by this paper
• Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice.

  1999cited by this paper
• Specific CD3 epsilon association of a phosphodiesterase 4B isoform determines its selective tyrosine phosphorylation after CD3 ligation.

  1999cited by this paper
• Differential inhibitory mechanism of cyclic AMP on TNF‐α and IL‐12 synthesis by macrophages exposed to microbial stimuli

  1999cited by this paper
• Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.

  1998cited by this paper
• Requirement for IL-13 independently of IL-4 in experimental asthma.

  1998cited by this paper
• SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions.

  1998cited by this paper
• Requirement for IL-13 independently of IL-4 in experimental asthma

  1998cited by this paper
• The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions.

  1998cited by this paper
• Interleukin-13: central mediator of allergic asthma.

  1998cited by this paper
• Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig.

  1998cited by this paper
• Interleukin-13: central mediator of allergic asthma

  1998cited by this paper
• Inhibition of eotaxin‐mediated human eosinophil activation and migration by the selective cyclic nucleotide phosphodiesterase type 4 inhibitor rolipram

  1997cited by this paper
• Regulation of IgE and cytokine production by cAMP: implications for extrinsic asthma.

  1996cited by this paper
• Selective inhibition of phosphodiesterase type IV suppresses the chemotactic responsiveness of rat eosinophils in vitro.

  1996cited by this paper
• Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model

  1996cited by this paper
• IL-13 expression at the sites of allergen challenge in patients with asthma.

  1995cited by this paper
• Elevated intracellular cyclic AMP inhibits chemotaxis in human eosinophils.

  1995cited by this paper
• Role of cyclic nucleotides and nitric oxide in blood mononuclear cell IgE production stimulated by IL-4.

  1995cited by this paper
• Beta-adrenoceptors, cAMP and airway smooth muscle relaxation: challenges to the dogma.

  1994cited by this paper
• Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma.

  1992cited by this paper
• Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects of 3',5'-cyclic adenosine monophosphate on cell replication in human T lymphocytes.

  1992cited by this paper
• Cyclic AMP directly inhibits IL-2 receptor expression in human T cells: expression of both p55 and p75 subunits is affected.

  1991cited by this paper
• Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation.

  1991cited by this paper
• Differential regulation of IL 6, IL 1 A, IL 1β and TNFα production in LPS-stimulated human monocytes: Role of cyclic AMP

  1990cited by this paper
• Differential regulation of IL 6, IL 1 A, IL 1 beta and TNF alpha production in LPS-stimulated human monocytes: role of cyclic AMP.

  1990cited by this paper
• Interleukin 4 causes isotype switching to IgE in T cell-stimulated clonal B cell cultures

  1988cited by this paper
• The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response.

  1988cited by this paper
• Regulation of interleukin 2 synthesis by cAMP in human T cells.

  1987cited by this paper

• Discovery, Synthesis, and Biological Evaluation of Novel Quinoline-Based PDE4 Inhibitors with Potent Anti-Chronic Obstructive Pulmonary Disease Activity.

  2026cites this paper
• Phosphodiesterase signaling in asthma: mechanistic insights and emerging therapeutic strategies.

  2026cites this paper
• The Mechanisms of Immunoglobulin E Sensitizations in Atopic Dermatitis.

  2025cites this paper
• PDE4B Inhibition: Exploring the Landscape of Chemistry Behind Specific PDE4B Inhibitors, Drug Design, and Discovery

  2025cites this paper
• Difamilast topically ameliorates pruritus, dermatitis, and barrier dysfunction in atopic dermatitis model mice by inhibiting phosphodiesterase 4, especially the 4B subtype.

  2025cites this paper
• PDE4B Modulates Phosphorylation of p65 (Ser468) via cAMP/PKA in Acute Lung Injury

  2025cites this paper
• Cyclic nucleotide phosphodiesterases as drug targets.

  2025cites this paper
• Rutaecarpine alleviates hepatic ischemia‒reperfusion injury in liver transplantation by inhibiting inflammatory response and oxidative stress

  2025cites this paper
• The cAMP-phosphodiesterase PDE4B2 controls peroxisome proliferator-activated receptor γ (PPARγ) expression and the initiation of adipogenesis in 3T3-L1 cells.

  2025cites this paper
• Prediction of food materials for the management of respiratory symptoms targeting PDE4B and NMDAR via Machine Learning approach

  2024cites this paper
• Menisoxoisoaporphine A, a novel oxoisoaporphine alkaloid from Menispermi Rhizoma, inhibits inflammation by targeting PDE4B

  2024cites this paper
• The need for inhaled phosphodiesterase inhibitors in chronic obstructive pulmonary disease

  2024cites this paper
• Ambroxol Hydrochloride: A Comprehensive Review on Industrial‐Scale Synthesis, Pharmacological Aspects & Therapeutic Applications

  2024cites this paper
• Off-Label Topical and Oral Roflumilast Treatment in Dermatology: A Systematic Review

  2024cites this paper
• Potential of phosphodiesterase 4B inhibitors in the treatment of interstitial lung disease associated with autoimmune diseases.

  2024cites this paper
• Targeting pro-inflammatory T cells as a novel therapeutic approach to potentially resolve atherosclerosis in humans

  2024cites this paper
• Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis

  2023cites this paper
• Dysregulated Cyclic Nucleotide Metabolism in Alcohol-Associated Steatohepatitis: Implications for Novel Targeted Therapies

  2023cites this paper
• Topical application of a PDE4 inhibitor ameliorates atopic dermatitis through inhibition of basophil IL-4 production.

  2023cites this paper
• Modulation of Human Dendritic Cell Functions by Phosphodiesterase-4 Inhibitors: Potential Relevance for the Treatment of Respiratory Diseases

  2023cites this paper
• Novel Anti-Inflammatory Approaches to COPD

  2023cites this paper
• Advances in the development of phosphodiesterase 7 inhibitors.

  2023cites this paper
• Transcriptional changes in dendritic cells underlying allergen specific induced tolerance in a mouse model

  2022cites this paper
• Clinical Implication of Phosphodiesterase-4-Inhibition

  2022cites this paper
• Ligustrazine Inhibits Lung Phosphodiesterase Activity in a Rat Model of Allergic Asthma

  2022cites this paper
• The effects of BRL-50481 on ovalbumin-induced asthmatic lung inflammation exacerbated by co-exposure to Asian sand dust in the murine model

  2022cites this paper
• Targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement.

  2022cites this paper
• PDE4B Is a Homeostatic Regulator of Cyclic AMP in Dendritic Cells

  2022cites this paper
• Coupling sparse Cox models with clustering of longitudinal transcriptomics data for trauma prognosis

  2021cites this paper
• Fermented Red Ginseng Alleviates Ovalbumin-Induced Inflammation in Mice by Suppressing Interleukin-4 and Immunoglobulin E Expression

  2021cites this paper
• The cAMP-phosphodiesterase 4 (PDE4) controls β-adrenoceptor- and CFTR-dependent saliva secretion in mice.

  2021cites this paper
• Insight into Inhibitory Mechanism of PDE4D by Dietary Polyphenols Using Molecular Dynamics Simulations and Free Energy Calculations

  2021cites this paper
• The Role of PDE8 in T Cell Recruitment and Function in Inflammation

  2021cites this paper
• New Avenues for Phosphodiesterase Inhibitors in Asthma

  2021cites this paper
• Assessment of PDE4 Inhibitor-Induced Hypothermia as a Correlate of Nausea in Mice

  2021cites this paper
• Synthesis and in vitro evaluation of anti-inflammatory, antioxidant, and anti-fibrotic effects of new 8-aminopurine-2,6-dione-based phosphodiesterase inhibitors as promising anti-asthmatic agents.

  2021cites this paper
• Ablation of PDE4B protects from Pseudomonas aeruginosa‐induced acute lung injury in mice by ameliorating the cytostorm and associated hypothermia

  2021cites this paper
• Novel pharmacological therapies for the treatment of bronchial asthma.

  2021cites this paper
• NCS 613, a Potent PDE4 Inhibitor, Displays Anti-Inflammatory and Anti-Proliferative Properties on A549 Lung Epithelial Cells and Human Lung Adenocarcinoma Explants

  2020cites this paper
• Advances in the development of phosphodiesterase-4 inhibitors.

  2020cites this paper
• Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.

  2020cites this paper
• The regulatory role of SFRP5/WNT5A axis in allergic rhinitis through inhibiting JNK pathway activation and lowering mucin generation in human nasal epithelial cells.

  2020cites this paper
• Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS.

  2020cites this paper
• Glucagon reduces airway hyperreactivity, inflammation, and remodeling induced by ovalbumin

  2019cites this paper
• Anti‑inflammatory effect of ciclamilast in an allergic model involving the expression of PDE4B.

  2019cites this paper
• Phosphodiesterases as therapeutic targets for respiratory diseases.

  2019cites this paper
• Anti-inflammatory Effects of Distylium racemosum Extract in a Mouse Model of Allergic Asthma

  2018cites this paper
• Quantitative structure–activity relationship modeling of S-triazines and 2-arylpyrimidines as selective PDE4B inhibitors

  2018cites this paper
• Phosphodiesterase 4B plays a role in benzophenone‐3‐induced phototoxicity in normal human keratinocytes

  2018cites this paper
• A pathophysiological role of PDE3 in allergic airway inflammation.

  2018cites this paper
• 3D QSAR Studies of 2-Arylpyrimidines and S-Triazines as Selective PDE4B Inhibitors

  2018cites this paper
• Ligand ‐ based methods : general aspects and perspective

  2018cites this paper
• A pathophysiological role of PDE 3 in allergic airway inflammation

  2018cites this paper
• In Utero Exposure To Second-Hand Smoke Aggravates Adult Responses To Inhaled Irritants

  2018cites this paper
• Pharmacophore Based Virtual Screening Approach to Identify Selective PDE4B Inhibitors

  2017cites this paper
• cAMP: a multifaceted modulator of immune synapse assembly and T cell activation

  2017cites this paper
• Selective Inhibition of Phosphodiesterases 4A, B, C and D Isoforms in Chronic Respiratory Diseases: Current and Future Evidences.

  2017cites this paper
• Computational Approaches in the Development of Phosphodiesterase Inhibitors

  2017cites this paper
• Phosphodiesterase 4B negatively regulates endotoxin-activated interleukin-1 receptor antagonist responses in macrophages

  2017cites this paper
• The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease

  2016cites this paper
• Identification and Characterization of Baicalin as a Phosphodiesterase 4 Inhibitor

  2016cites this paper
• Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi

  2015cites this paper
• Phosphodiesterase 4B is essential for lipopolysaccharide-induced CC chemokine ligand 3 production in mouse macrophages

  2015cites this paper
• Neutrophil migration and inflammation in chronic obstructive pulmonary disease

  2015cites this paper
• Asthma Pharmacogenomics: 2015 Update

  2015cites this paper
• Phospholipase Cε, an Effector of Ras and Rap Small GTPases, Is Required for Airway Inflammatory Response in a Mouse Model of Bronchial Asthma

  2014cites this paper
• Functional characterization of Phosphodiesterase-4A in behavior and obesity

  2014cites this paper
• Modulation of respiratory mucosal immunity against pulmonary tuberculosis

  2014cites this paper
• PDE inhibitors currently in early clinical trials for the treatment of asthma

  2014cites this paper
• Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease.

  2014cites this paper
• Current and novel bronchodilators in respiratory disease

  2014cites this paper
• Discovery of triazines as selective PDE4B versus PDE4D inhibitors.

  2014cites this paper
• Phosphodiesterase inhibitors as therapeutics for traumatic brain injury.

  2014cites this paper
• Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior

  2014cites this paper
• Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP.

  2014cites this paper
• The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma

  2014cites this paper
• Advances in targeting cyclic nucleotide phosphodiesterases

  2014cites this paper
• Mitogen-activated Protein Kinase Phosphatases in Inflammation and as Anti-inflammatory Drug Targets

  2014cites this paper
• New era of biologic therapeutics in atopic dermatitis

  2013cites this paper
• Efeito do glucagon sobre a contração da musculatura lisa das vias aéreas de camundongos A/J

  2013cites this paper
• The Toxicant Induction of Irritant Asthma, Rhinitis, and Related Conditions

  2013cites this paper
• PDE4 as a target for cognition enhancement

  2013cites this paper
• Regulatory T-cells and cAMP suppress effector T-cells independently of PKA-CREM/ICER: a potential role for Epac.

  2013cites this paper
• The Yin Yang of Hormones that Control Glucose Homeostasis in Asthma

  2013cites this paper
• Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase‐1

  2013cites this paper
• Products of Tobacco Combustion

  2013cites this paper
• cAMP‐Specific Phosphodiesterases: Modulation, Inhibition, and Activation

  2012cites this paper
• Phosphodiesterase 4 and its inhibitors in inflammatory diseases.

  2012influential citation
• Selective PDE inhibitors as novel treatments for respiratory diseases.

  2012cites this paper
• Phosphodiesterase Inhibitors in Obstructive Lung Disease

  2012cites this paper
• CHAPTER 1 cAMP-Specific Phosphodiesterases : Modulation , Inhibition , and Activation

  2012cites this paper
• The β 2-Adrenergic Receptor Agonists Pathway

  2012cites this paper
• In utero exposure to second-hand smoke aggravates adult responses to irritants: adult second-hand smoke.

  2012cites this paper
• Therapeutic Potential of ASP3258, a Selective Phosphodiesterase 4 Inhibitor, on Chronic Eosinophilic Airway Inflammation

  2012cites this paper
• Cyclic Nucleotide Phosphodiesterases (PDEs) in Smooth Muscle : Expression, Function and Mechanism

  2012cites this paper
• New therapeutic options in the management of COPD – focus on roflumilast

  2011cites this paper
• Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood

  2011cites this paper
• The pharmacogenetics and pharmacogenomics of asthma therapy

  2011cites this paper
• AMPc i neuroinflamació: Identificació de proteïnes implicades en la regulació dels nivells d’AMPc en l’encefalomielitis autoimmune experimental

  2011cites this paper